Thomas Marron
Icahn School of Medicine at Mount Sinai · Assistant Director
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Thomas Marron as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:25 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07284485 · Immunoprevention for High-risk Lung LesionsRobert Samstein · recruiting · High-risk Lung Nodules · study chair
- Ph1/Ph2NCT07277322 · Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver MetastasesDan Feng · recruiting · Metastatic Colorectal Cancer, Liver Metastases · study chair
- Ph1NCT07058974 · A Study of Exercise and Pharmacologic Intervention on Systemic InflammationIcahn School of Medicine at Mount Sinai · active not recruiting · Smokers, Former Smokers · principal investigator
- Ph1/Ph2NCT06494579 · Lamivudine for Solid TumorsThomas Marron · active not recruiting · Relapsed/Refractory Solid Tumors · principal investigator
- Ph1/Ph2NCT06088771 · Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCIcahn School of Medicine at Mount Sinai · recruiting · Non-Small Cell Lung Cancer · principal investigator
- Ph1/Ph2NCT05013450 · Dupilumab_Metastatic NSCLCThomas Marron · active not recruiting · Metastatic Non-small Cell Lung Cancer · principal investigator
- Ph1NCT04525859 · Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural MesotheliomaOncovir, Inc. · completed · Malignant Pleural Mesothelioma · study director
- Ph2NCT04388709 · Interferon Lambda Therapy for COVID-19Icahn School of Medicine at Mount Sinai · withdrawn · SARS-CoV-2 · principal investigator
- Ph2NCT04123379 · Neoadjuvant Nivolumab With CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)Icahn School of Medicine at Mount Sinai · active not recruiting · Non-small Cell Lung Cancer, Hepatocellular Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:25 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Breaking the Myeloid-Stromal Axis to Treat Colorectal CancerR01CA308427 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2026 · $697,131 awarded in 2026Same name and institution; not confirmed by an ID
- Type 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalkR01CA277479 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · fiscal years 2023 to 2026 · $658,328 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:25 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination.Nat Med · 2019363 citationsRCR 11.5
- Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.Nat Med · 2024235 citationsRCR 26.1
- Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial.Lancet Gastroenterol Hepatol · 2022211 citationsRCR 13.7
- 171 citationsRCR 17.0
- 70 citationsRCR 35.0
- Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.Cancer Immunol Res · 202065 citationsRCR 2.4
- Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer.J Immunother Cancer · 202231 citationsRCR 1.9
- PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting.Cancer Discov · 202529 citationsRCR 5.4
- Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.ESMO Open · 202419 citationsRCR 2.1
- Safety and efficacy of intratumoral MEDI1191, an IL-12 mRNA lipid nanoparticle, plus intravenous durvalumab in patients with advanced solid tumors: a first-in-human study.Clin Cancer Res · 202611 citationsRCR 5.5